Tag: biotechnology
-
Zymeworks, Janssen in $1.45B Antibody Licensing Deal
Janssen Biotech, a division of drug maker Johnson & Johnson, is acquiring technologies that make it possible to create synthetic antibodies that hit multiple targets.
-
Sanofi Acquires Multiple Sclerosis Drug in $800M Deal
Drug maker Sanofi is licensing a drug candidate from Principia Biopharma Inc. designed to treat multiple sclerosis, an autoimmune condition affecting the brain and nervous system.
-
New Drug Shown to Reduce Depressive Behaviors
A new type of treatment for depression that works differently from most other anti-depressive drugs was shown in lab mice to reduce depression-like behaviors.
-
Start-Up Formed to Develop Non-Opioid Pain Drugs
A new enterprise is being formed to develop non-addictive drugs for chronic pain that use different biochemical processes than opioid pain relievers.
-
RNA Meds Companies Partner on Human, Animal Vaccines
Synthetic Genomics Inc. and Arcturus Therapeutics Inc. are collaborating on longer-lasting and more robust RNA therapies and vaccines for humans and animals.
-
Novartis Acquires Nuclear Meds Developer in $3.9B Deal
Drug maker Novartis is purchasing a company that develops therapies and diagnostics using radio isotopes for neuroendocrine and other cancers.
-
Multi-Drug Resistance Antibiotic Developer to Issue IPO
A three year-old company making new antibiotics to treat infections resistant to earlier antibiotics plans to raise some $75 million in its initial public stock offering.
-
Biosimilars Seen Saving U.S. $54 Billion
An analysis of health care costs shows increasing the use of substitute biologic treatments known as biosimilars could save the United States some $54 billion over 10 years.
-
Live Skin Bacteria Shown to Control Acne
First results of a clinical trial show a spray-on formulation of live bacteria reduced the amount and severity of acne in people with mild to moderate cases of the condition.
-
Lilly, CureVac Partner on RNA Cancer Drugs in $1.8B Deal
Drug maker Eli Lilly and Company and biotechnology company CureVac AG agreed to develop a series of cancer immunotherapies based on CureVac’s messenger RNA technology.